推薦產品
等級
pharmaceutical primary standard
API 家族
codergocrine
製造商/商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
CS(O)(=O)=O.CC(CO)NC(=O)C1CC2C(Cc3c[nH]c4cccc2c34)N(C)C1
InChI
1S/C19H25N3O2.CH4O3S/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13;1-5(2,3)4/h3-5,8,11,13,15,17,20,23H,6-7,9-10H2,1-2H3,(H,21,24);1H3,(H,2,3,4)
InChI 密鑰
ONYMVHQTXOEAOV-UHFFFAOYSA-N
尋找類似的產品? 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Codergocrine mesilate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
International journal of pharmaceutics, 375(1-2), 16-21 (2009-06-09)
The aim of this investigation was to prepare ergoloid mesylate submicron emulsions (EMSEs) for enhancing nasal absorption of drug and reducing nasal ciliotoxicity. Following intranasal administrations of EMSE and ergoloid mesylate solution (EMS) and intravenous administration of EMS to rats
Drugs to treat Alzheimer's disease.
Journal of psychosocial nursing and mental health services, 47(4), 13-14 (2009-05-15)
Terapevticheskii arkhiv, 72(11), 47-50 (2001-03-29)
To assess a hypotensive effect of redergin (dihydroergotoxin)--agonist of dopaminergic receptors--in monotherapy (4.5-6 mg/day) and in combination with enalapril and amlodipin (10 mg/day). Redergin in monotherapy or combined therapy was given to 106 hypertensive women in pre- or postmenopause and
The Cochrane database of systematic reviews, (2)(2), CD000359-CD000359 (2000-05-05)
Currently hydergine is used almost exclusively for treating patients with either dementia, or 'age-related' cognitive symptoms. Since the early eighties there have been over a dozen more clinical trials, yet hydergine's efficacy remains uncertain. Although previous reviews offer generally favorable
[Can a hydergine therapy lead to damage of the coronary vessels?].
Deutsche medizinische Wochenschrift (1946), 127(25-26), 1401-1401 (2002-07-24)
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務